On January 5, 2024, a Delaware federal court issued a ruling in favor of Sarepta Therapeutics in a patent lawsuit against Regenxbio and the University of Pennsylvania. The case involved a dispute over the patent for a Duchenne muscular dystrophy (DMD) treatment. Sarepta’s gene therapy product, Elevidys, approved by the FDA for DMD, was at the center of this legal battle.
U.S. District Judge Richard Andrews ruled that the patent claimed by Regenxbio, which was based on naturally occurring DNA sequences, was invalid. This decision has implications for the biotech industry, particularly in the field of gene therapy and patent law. While Regenxbio expressed disappointment and plans to appeal, Sarepta welcomed the decision.
The case, Regenxbio Inc v. Sarepta Therapeutics Inc, reflects the intricate dynamics of patent rights, medical innovation, and commercial interests in the healthcare sector. It highlights the challenges and complexities involved in developing and protecting new medical treatments.
1. Regenxbio Inc v. Sarepta Therapeutics Inc, U.S. District Court for the District of Delaware, No. 1:20-cv-01226
2.https://www.prnewswire.com/news-releases/us-district-court-issues-decision-on-regenxbio-and-university-of-pennsylvania-nav-technology-patent-infringement-lawsuit-302028115.html
Related News
NeuExcell’s NXL-004 Secures FDA Orphan Drug Designation for Glioma Treatment
On December 7, 2023, Beijing time, NeuExcell Therapeutics announced that its proprietary AAV gene therapy product, NXL-004, designed for treating malignant glioma, has been awarded Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). This...
PackGene Biotech Receives Exclusive C+ Round Investment from SDIC Fund, and Hosts a CGT Industry Salon to Discuss Global Strategies
December 1, 2023, PackGene Biotech, a frontrunner in gene therapy delivery, has successfully closed a landmark C+ funding round, securing over 100 million RMB exclusively from SDIC Fund Management Co., Ltd. This funding, a remarkable accomplishment in the current...
Tauopathy’s Role in Aβ Oligomer Formation: New Insights from Transgenic Primate Models on Alzheimer’s Pathogenesis
Tauopathy, characterized by protein tau and Aβ oligomer accumulation, is a significant aspect of Alzheimer's disease. The causal relationship between these accumulations and neurodegeneration remains unclear despite their links to various cognitive and movement...
Targeted Lysosomal Degradation of Mutant Huntingtin by Engineered Intrabody Peptide SM3
Huntington's disease (HD) is a devastating neurodegenerative condition caused by a mutation in the Huntingtin gene (HTT). This leads to the production of a mutant form of the huntingtin protein (mHTT) with an extended polyglutamine (polyQ) repeat, which has a...
Related Services
Plasmid CDMO Services
We provide high quality plasmids that are ideal for any phase of the drug development cycle.
READ MORE
AAV cGMP Manufacturing
READ MORE
AAV Capsid Engineering
Proven technology paving your path to effective therapies for cancer or genetic disorder
READ MORE
